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Abstract
Therapeutic oligonucleotides, such as splice switching ONs (SSOs), provide opportunities for 
treating serious, life-threatening diseases. However, the development of ONs as therapeutic agents 
has progressed slowly, because difficult cytosolic delivery of SSOs into the cytosol and nucleus 
remains a major barrier. Photochemical internalization (PCI), a promising strategy for endosomal 
escape, was introduced to disrupt the endosomal membrane using light and a photosensitizer. Here 
we constructed Poly(amido amine) (PAMAM) dendrimer conjugates to simultaneously deliver 
SSOs and photosensitizers into endo/lysosomal compartments. After photo-irradiation, 
considerable ONs were observed to diffuse into the cytosol and accumulate in the nucleus. 
Furthermore, the PCI mediated cytosolic delivery of SSOs effectively enhanced their nuclear 
splice switching activity.
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Introduction
There is great interest in therapeutic oligonucleotides (ONs), such as siRNA and antisense 
oligonucleotides (ASOs), in treating various diseases.1–3 Splice switching oligonucleotide 
(SSO), a type of therapeutic ON, can hybridize to targeted nuclear pre-mRNA and block 
access of other splicing factors to modulate alternative splicing and subsequent gene 
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expression. SSOs have been tested for treating Duchenne muscular dystrophy in clinical 
trials and treating cancers in preclinical studies.4, 5 For instance, a SSO can redirect Bcl-x 
splicing from anti-apoptotic Bcl-xL to pro-apoptotic Bcl-xS and subsequently induce 
apoptosis of tumor cells.6, 7 Despite the great potential as novel therapeutic agents, the 
development of SSOs as therapeutic agents has progressed slowly.8, 9 A major impediment 
has been the difficult delivery of these large, hydrophilic and often charged macromolecules 
from endosomal compartments into cytosol or nucleus of cells.10 One promising strategy to 
overcome this intracellular barrier is photochemical internalization (PCI) that disrupts the 
endosomal membrane using light and photosensitizer (PS).11–13 Nobuhiro Nishiyama and 
coworkers suggested that the subcellular localization of PSs might be the key to achieve 
cytosolic delivery with low non-specific photo-toxicity using PCI approach.12 When the PSs 
distributed in photodamage-sensitive organelles such as cytoplasmic membrane and 
mitochondria, they produced severe photo-toxicity and diminished PCI-mediated cytosolic 
delivery of therapeutic ONs.14, 15
In this study, we aimed to link both ONs and PSs in poly(amido amine) (PAMAM) 
dendrimer, and thereafter cellular delivery of the dendritic conjugates allows spatiotemporal 
distribution of the two modalities within endo/lysosomal compartments for superior delivery 
of ONs. We chose phosphorodiamidate morpholino oligomer (PMO), a third generation of 
ON, to construct the dendritic conjugates as PMO is a non-charged ON16, 17 and can 
decrease the cytotoxicity of the highly positively charged dendrimers. We utilized a 
reductively responsive disulfide bond to link PMO to PAMAM. Then Ce6 was activated and 
conjugated to the residual amino on the surface of PAMAM (Fig. 1). Cellular delivery of the 
dendritic conjugates leads to co-localization of the PMO and Ce6 in the endo/lysosomal 
compartments. Further light irradiation causes great functional delivery of the PMO.
Materials and Methods
Preparation of PMO-PAMAM-Ce6 conjugates
The PMO SSO (5′-GTTATTCTTTAGAATGGTGC-3′) was synthesized by Gene Tools, 
LLC (Philomath, OR, USA). PMO was functionalized with a disulfide amide for sulfhydryl 
linkage at the 3′ position (PMO-S-S-R). The amino groups of the PAMAM (generation 5.0, 
Dendritech, Inc.) were reacted with the bifunctional crosslinker N-succinimidyl 3-(2-
pyridyldithio) propionate (SPDP, Thermo Fisher Scientific) at a 1:25 molar ratio of 
PAMAM to linker in PBS (1 mM EDTA, pH 7.5) for 1 h at room temperature. The thiol 
group of PMO was freshly generated by incubating PMO-S-S-R with 10 mM DTT for 1 h at 
room temperature, and any residual DTT was removed by gel filtration (Sephadex G-25, GE 
Healthcare). PAMAM-SPDP was then reacted with the thiol group of PMO at the molar 
ratio of 1:25 in PBS (1 mM EDTA, pH 7.0) overnight, and the product was purified by gel 
filtration (Sephadex G-100) to obtain PMO-PAMAM.
Ce6 (MedKoo Biosciences Inc.) was dissolved in DMSO, followed by the addition of 10 
molar equivalents of EDC and Sulfo-NHS (Thermo Fisher Scientific). After overnight 
incubation, activated Ce6 (Ce6-NHS) was added to PMO-PAMAM with a 15:1 molar ratio 
and incubated for 12 hrs in dark at room temperature. After that, the product was purified by 
gel filtration (Sephadex LH-20, GE Healthcare) to remove unconjugated Ce6, and the 
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mobile phase was mixture of methanol and distilled water (v/v=1:3). Then the solvent was 
removed under vacuum, the PMO-PAMAM-Ce6 were redistributed in PBS. The 
concentration of PMO and Ce6 of PMO-PAMAM-Ce6 conjugates were detected by the 
260nm and 403nm absorbance, respectively.
In order to prepare labelled conjugates that were used in flow cytometry and imaging 
experiments, a PMO that is functionalized with a primary amine at the 5′ position and a 
disulfide amide for sulfhydryl linkage at the 3′ position was synthesized by Gene Tools, 
LLC. The PMO was labelled with Alexa Fluor® 488 NHS Ester (Life Technologies) and 
was referred as PMO488. Then PMO488 was used to prepare fluorescent conjugates termed 
as PMO488-PMO-Ce6.
Physical Characterization of PMO-PAMAM-Ce6 conjugates
The size and zeta potential of PMO-PAMAM-Ce6 was evaluated using a Zetasizer Nano 
(Malvern Instruments). To test the release profile, PMO-PAMAM-Ce6 conjugates were 
incubated with PBS containing 10mM glutathione (GSH) at 37°C for 4 h, and PBS was used 
as a control. After incubation, two samples were eluted by Sephadex G-100 with 0.5ml 
sample per tube. The PMO concentration in each fraction was detected by Nanodrop 1000 
(Thermo Scientific, Wilmington, DE) at 260nm absorbance.
Cellular uptake
A375 cells were cultured in DMEM medium (Life Technologies) containing 10% fetal 
bovine serum (Sigma). After attachment, the cells were incubated with PMO488-PAMAM-
Ce6 (400nM of Ce6) for 12 hrs. Equivalent free PMO488 and Ce6 were incubated with cells 
as well. After that, the cellular uptake was measured by flow cytometry using a LSR II cell 
analyzer (Becton-Dickenson, CA), with QD655 channel for Ce6 and FITC channel for 
PMO488.
Subcellular distribution
Intracellular distribution of PMO488-PAMAM-Ce6 in A375 cells was observed using 
OLYMPUS FV1200 confocal microscope. Fifty thousand cells were seeded on glass coated 
dishes (MatTek, MA) and incubated for attachment. Subsequently, PMO488-PAMAM-Ce6 
(400nM of Ce6) was added into the cells for 12-h incubation. After that, cells were observed 
by confocal microscopy, with QD655 channel for Ce6 and Alexa 488 channel for PMO488. 
In addition, intracellular distribution of PMO488-PAMAM and free Ce6 (5μM) was detected 
by confocal as well. Lysotracker Red was used to detect the subcellular distribution of 
PMO488-PAMAM-Ce6 in A375 cells. Cells were treated with PMO488-PAMAM-Ce6 
(400nM of Ce6) for 12 hrs, followed by incubation with 100nM Lysotracker Red for 1 h 
prior to confocal imaging. Alexa 488 channel was used for detection of PMO488, and Alexa 
594 channel was used for Lysotracker Red.
Light activated endosomal release
Confocal imaging was performed to detect the PCI mediated endosomal release of PMO488-
PAMAM-Ce6 upon photo-irradiation. A375 cells were seeded on glass coated dishes and 
incubated for attachment. PMO488-PAMAM-Ce6 (50nM of Ce6) was added and incubated 
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for 12 hrs. After that, cells were washed twice with fresh media and photo-irradiated for 
20min. After incubation with another 12 hrs, the cells were imaged by confocal microscopy, 
and the images were collected with a 60× oil immersion lens.
PCI induced eGFP expression
A375/eGFP654 cells were seeded on 48-well plates at the density of 30,000 cells per well. 
After one day, cells were treated by free PMO (125nM) and PMO-PAMAM-Ce6 (50nM of 
Ce6 and 125nM of PMO). After 12-h treatment, cells were washed twice with fresh media. 
After that, cells treated by PMO-PAMAM-Ce6 were photo-irradiated by a 660nm laser for 
20min. After a day, cells were trypsinized and their eGFP expression was detected by flow 
cytometry. Cells treated by PBS were set as negative control and cells treated by 
Lipofectamine 2000 (L2K) complexes of negatively charged phosphorothioate ONs (the 
same concentration and sequence) were set as positive control. The cell viability of A375/
eGFP654 cells after the same treatments was examined using Alamar Blue assay (Life 
Technologies). eGFP expression in A375/eGFP654 cells was also observed by confocal 
imaging using OLYMPUS FV1200.
Data analysis
Data are expressed as mean ± SD from three measurements unless otherwise noted. 
Statistical significance was evaluated using t-test for two-sample comparison or ANOVA 
followed by Dunnet’s test for multiple comparisons. The data were analyzed with GraphPad 
Prism 5 (GraphPad Software, Inc., La Jolla, CA).
Results
Preparation and characterization of PMO-PAMAM-Ce6 conjugates
PAMAM was modified with SPDP and then reacted with the thiol group at the 3′ end of 
PMO. The obtained products were purified with Sephadex G-100 column to remove 
unreacted PMO. NHS activated Ce6 was conjugated to PMO-PAMAM to obtain PMO-
PAMAM-Ce6, and the conjugates were further purified with Sephadex LH-20 (Fig. S1). The 
molar ratio of PMO to Ce6 on PMO-PAMAM-Ce6 conjugates was demonstrated as 2.5:1, 
according to the absorbance in 260nm and 403nm, respectively (Fig. S1).
The diameter of PMO-PAMAM-Ce6 conjugates is 21.1nm (Fig. S2), measured by dynamic 
light scattering (DLS). The zeta potential of PMO-PAMAM-Ce6 conjugates is +2.2mV (Fig. 
S3). The significant decrease of zeta potential from about +17mV of PAMAM to +2.2mV of 
PMO-PAMAM-Ce6 are primarily due to the amine blocking and the modification of PMO 
and Ce6 molecules.
Next we tested whether intracellular sulfhydryl can release the PMOs from the PMO-
PAMAM-Ce6 conjugates using PBS containing 10mM GSH (Fig. 2). In gel filtration 
(Sephadex G-100 column) of the GSH treated sample, 85.9% of PMOs were eluted slower 
(between 16 to 30 fractions) and were separated from the conjugates content (between 4 to 
11 fractions), indicating that the majority of PMOs could be cleaved from the conjugates in 
the cellular reducing environment.
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To compare the cellular uptake of PMO-PAMAM-Ce6 conjugates to free PMOs and Ce6, 
we labelled fluorescent Alexa-488 to PMO, and then successively conjugated PMO488 and 
Ce6 to PAMAM. Cellular uptake was evaluated by incubating cells with PMO488, free Ce6 
and PMO488-PAMAM-Ce6, followed by flow cytometry (Ex 488nm, Em 525/20nm for 
PMO488; Ex 405nm, Em 655/20 for Ce6). As shown in Fig. 3, Free PMO488 did not enter 
into the cells significantly, but the dendritic conjugates showed substantial cellular uptake 
(Fig. 3A). Similarly, the Ce6 fluorescence from PMO488-PAMAM-Ce6 was also 
significantly higher than that of free Ce6 group (Fig. 3B). These results indicated that the 
conjugation of PMO and Ce6 to PAMAM together facilitated their internalization, which 
might be contributed to effective intracellular internalization of PAMAM dendrimers.18, 19
Intracellular distribution of PMO-PAMAM-Ce6 conjugates
Following cellular internalization, the spatial distribution of PMO488 and Ce6 after 12-h 
incubation with PMO488-PAMAM-Ce6 conjugates was observed using confocal imaging. 
The images demonstrated that red punctate fluorescence of Ce6 completely colocalized with 
green fluorescence of PMO488 in the cytoplasm (Fig. 4). However, in the cells treated with 
PMO488-PAMAM and free Ce6, diffused red Ce6 fluorescence merely exhibited partial 
colocalization with green PMO488 (Fig. S4). We quantified the colocalization between 
PMO488 and Ce6 using Pearson’s correlation coefficient (PCC). In the PMO488-PAMAM-
Ce6 conjugates group, the PCC value was 0.76, which was significantly higher than that in 
PMO-PAMAM with free Ce6 group (PCC=0.283, p<0.001, Fig. S5). These results 
confirmed their spatiotemporal co-localization of the two modalities. The complete 
colocalization between ONs and PSs provided the possibility for superior cytosolic delivery 
of ONs as well as reduced photo-toxicity. In addition, intracellular localization of the 
fluorescent conjugates was also detected with Lysotracker. Green fluorescent punctuates of 
conjugates were largely colocalized with Lysotracker Red, indicating that PMO488-
PAMAM-Ce6 located in the acidic vesicular organelles, including late endosomes and 
lysosomes (Fig. S6).
Next, we examined the light-activated delivery of ONs to nucleus, where PMO interacts 
with its target pre-mRNA (Fig. 5A). Without photo-irradiation, fluorescent PMO was 
confined to endo/lysosomal compartments without obvious fluorescent signal in cytosol and 
nucleus. However, in the cells treated with PMO488-PMO-Ce6 and followed by photo-
irradiation, diffused green fluorescence was observed in the cytosol and nucleus region (Fig. 
5B). The percentage of nuclear fluorescent signal to the whole cells significantly increased 
from 6.7% to 27% when cells were photo-irradiated (Fig. 5C).
PCI mediated eGFP induction
Finally, functional delivery by PMO-PAMAM-Ce6 followed by photo-irradiation was 
examined by flow cytometry and confocal imaging (Fig. 6). A375 cells were stably 
transfected with eGFP expression cassettes containing a mutated intron and were referred as 
A375/eGFP654 cells. A model SSO targets an intronic splice site and causes splicing out of 
the intron and expression of wild-type eGFP protein (Fig. 6A).20–22 eGFP induction of 
A375/eGFP654 cells without any treatment was set as control. A375/eGFP654 cells treated 
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by free PMO (125nM) did not induce eGFP expression as the fluorescent peak coincides 
with the negative control. Compared with the negative control, the mean eGFP fluorescence 
of cells treated by PMO-PAMAM-Ce6 (PMO 125nM; Ce6 50nM) with or without photo-
irradiation increased by 18.9- and 2.8- fold, respectively. PMO-PAMAM-Ce6 significantly 
increased functional delivery of the SSO in a light-activated manner (Fig. 6B). In addition, 
the cells treated with Lipofectamine 2000(L2K) complexes of PS ON (125nM) exhibited 
5.9-fold eGFP induction, which was significantly lower than that of the PMO-PAMAM-Ce6 
with photo-irradiation group (Fig. S7). Meanwhile, nearly 92% of cells treated by PMO-
PAMAM-Ce6 with photo-irradiation were induced to express eGFP, in comparison with 
39.2% in cells treated with L2K/PS ONs (Fig. S8). Moreover, these flow data was 
confirmed by the confocal images (Fig. 6C). In control group, no obvious green 
fluorescence could be observed. Cells treated by PMO-PAMAM-Ce6 exhibited dim green 
fluorescence. However, strong green fluorescence was observed in almost all the cells in the 
PMO-PAMAM-Ce6 plus photo-irradiation group. These results strongly suggested that 
dendritic conjugates can produce effective delivery of ONs after photo-irradiation.
Discussion
PMO is a type of third generation ONs and has exhibited excellent chemical stability and 
resistance to nucleases and proteases in vitro and in vivo.23 PMO has been tested as a 
therapeutic agent in both animal models and human clinical trials.24, 25 However, in these 
applications, high dose of PMOs is needed to achieve these positive therapeutic outcomes. 
Poor cellular uptake [8] and insufficient endosomal escape [13] are two main causes for this 
clinical predicament. PMOs must be delivered to the cytosol of target cells to produce 
pharmacological actions. Once in the cytosol, PMOs can freely diffuse between the cytosol 
and nucleus. To facilitate the internalization, we conjugate multiple PMOs onto the positive 
charged PAMAM dendrimers. For effective endosomal release of PMOs, we introduce PS 
Ce6 to PMO-PAMAM conjugates to obtain PMO-PAMAM-Ce6 for photochemical 
internalization (PCI). There are some advantages for the simultaneous conjugation of PMOs 
and Ce6: (1) facilitating the internalization of these two modalities into cells; (2) 
guaranteeing their spatiotemporally colocalization in endo/lysosomal compartments; (3) 
avoiding the distribution of PSs in photo-damage sensitive organelles, including cytoplasmic 
membrane and mitochondria. These features have led to the effective light-activated 
cytosolic delivery of ONs as well as reduced phototoxicity.
We selected PAMAM dendrimers for co-delivery of PMOs and Ce6 because of three 
advantages of PAMAM dendrimers over linear polymers such as polyethylenimine. Firstly, 
PAMAM dendrimers have more surface amine groups than linear PEI polymers for linking 
ONs and PSs. Secondly, PAMAM dendrimers are monodisperse macromolecules, unlike 
linear polymers. Thus, we can obtain homogenous conjugates by using dendrimers. Third, 
linear chains exist as flexible coils in solution; while dendrimers form a tightly packed ball. 
The globular architecture of the dendrimers makes their end groups more accessible for 
conjugation of cargo molecules.
The cytotoxicity of the photo-irradiation could be observed during the process of PCI. In the 
absence of photo-irradiation, PMO-PAMAM-Ce6 did not show obvious dark cytotoxicity. 
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While upon photo-irradiation, the efficient PCI mediated cytosolic delivery was 
accompanied with approximately 20% decrease in the cell viability (Fig. S9). Compared 
with Lipofectamine 2000 (L2K), PMO-PAMAM-Ce6 conjugates plus photo-irradiation 
caused similar cytotoxicity, but significant higher induced eGFP expression (Fig. S7 and 
S9). During the PCI, endo/lysosomal membranes are destructed by ROS to release ONs. 
Meanwhile, leakage of some cytotoxic lysosomal proteases into cytosol is inevitable.26
In summary, we constructed dendritic conjugates to simultaneously deliver ONs and PSs 
into endo/lysosomal compartments. Upon light activation, PMOs are delivered to the 
nucleus and then bind to the target pre-mRNA. Furthermore, light-activated delivery using 
our dendritic conjugates has achieved functional delivery of ONs that is superior to the gold 
standard Lipofectamine transfection. To our best knowledge, this has been the first study of 
using dendrimers to prepare ON conjugates for light-activated delivery of ONs, and this 
study may thus provide a novel approach for functional delivery of therapeutic ONs 
including siRNAs, antisense ONs, SSOs, and antagomirs to microRNAs and long non-
coding RNAs.
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Preparation of PMO-PAMAM-Ce6 conjugates and schematic illustration showing the 
process of light-activated endosomal escape of the PMO.
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PMOs release profile from PMO-PAMAM-Ce6 by 10mM Glutathione.
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Comparison of cellular uptake of PMO-PAMAM-Ce6 to free PMO and Ce6 in A375 cells. 
Alexa Fluor® 488 was labelled to PMO to form PMO488-PAMAM-Ce6. (A) Cellular uptake 
of PMOs in FITC channel. Red: Control, Green: Free PMO488 and Blue: PMO488-PAMAM-
Ce6. (B) Cellular uptake of Ce6 in QD655 channel. Red: Control, Green: Free Ce6 and 
Blue: PMO488-PAMAM-Ce6.
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Colocalization of PMO488 and Ce6 in A375 cells. Cells were incubated with PMO488-
PAMAM-Ce6 for 12 hours. Scale bars, 50μm.
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(A) Schematic diagram of PCI mediated of cytosolic delivery of fluorescent PMOs. (B) 
Redistribution of released PMO488 from PMO488-PAMAM-Ce6 without (upper) or with 
(below) photo-irradiation in A375 cells. Scale bars, 5μm. (C) Quantification of the 
percentage of nuclear fluorescent signal to whole cells. The percentage was shown as mean 
and standard deviation obtained from 10 cells.
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Induction of eGFP by PMO-PAMAM-Ce6 with or without photo-irradiation. (A) The eGFP 
cDNA (green) is interrupted by an aberrantly spliced intron in which a portion (red) is 
spliced into the mRNA, producing aberrant eGFP (nonfluorescent). Blocking the aberrant 
splice site within the intron with a PMO prevents aberrant splicing and restores the reading 
frame of the eGFP to produce wild-type eGFP (fluorescent).20–22 (B) Flow cytometry of 
eGFP expression in A375/eGFP654 cells treated with free PMO, PMO-PAMAM-Ce6 with 
or without photo-irradiation. PBS treatment was set as a negative control and L2K/PS ON 
complexes treatment was set as positive control. (C) Confocal images of A375/eGFP654 
cells treated by PMO-PAMAM-Ce6 with or without photo-irradiation and L2K/PS ON 
complexes. Bar=50μm.
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